Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab Plus Chemotherapy for Unresectable Stage III NSCLC
NCT07139041Phase 2Not yet recruiting
- Sponsor
- Changchen Pharmaceutical
- Start
- Oct 2025
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab + tuvonralimab in non-small cell lung cancer (NSCLC), sponsored by Changchen Pharmaceutical. Primary endpoint: R0 Resection Rate at 2 years. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07139041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07139041.